| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 11/21/2023 | 23.44% | Baird | $4 → $0.75 | Downgrades | Outperform → Neutral |
| 11/20/2023 | 130.41% | TD Cowen | $6 → $1.4 | Downgrades | Outperform → Market Perform |
| 10/24/2023 | 1216.66% | Morgan Stanley | $14 → $8 | Maintains | Equal-Weight |
| 10/12/2023 | 311.45% | UBS | $7 → $2.5 | Maintains | Buy |
| 09/19/2023 | 1545.82% | Canaccord Genuity | → $10 | Reiterates | Buy → Buy |
| 08/07/2023 | 2204.15% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 08/04/2023 | 1545.82% | Baird | $13 → $10 | Maintains | Outperform |
| 05/08/2023 | 2368.73% | Morgan Stanley | $16 → $15 | Maintains | Equal-Weight |
| 03/02/2023 | 2533.31% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
| 02/02/2023 | 2368.73% | UBS | → $15 | Initiates Coverage On | → Buy |
| 11/09/2022 | 2697.89% | Morgan Stanley | $28 → $17 | Maintains | Equal-Weight |
| 11/08/2022 | 3849.97% | Cowen & Co. | $31 → $24 | Maintains | Outperform |
| 11/08/2022 | 2204.15% | Baird | $21 → $14 | Maintains | Outperform |
| 08/08/2022 | 4508.29% | Morgan Stanley | $30 → $28 | Maintains | Equal-Weight |
| 05/11/2022 | 4837.46% | Morgan Stanley | $45 → $30 | Maintains | Equal-Weight |
| 04/13/2022 | 5989.53% | Canaccord Genuity | $50 → $37 | Maintains | Buy |
| 03/24/2022 | 8129.1% | Canaccord Genuity | → $50 | Initiates Coverage On | → Buy |
| 03/02/2022 | 11420.74% | JP Morgan | $85 → $70 | Maintains | Overweight |
| 05/11/2021 | 10597.83% | Morgan Stanley | $70 → $65 | Maintains | Equal-Weight |
| 03/03/2021 | 11420.74% | Morgan Stanley | $55 → $70 | Maintains | Equal-Weight |
| 01/06/2021 | 12243.65% | Cowen & Co. | → $75 | Upgrades | Market Perform → Outperform |
| 12/03/2020 | 8952.01% | Morgan Stanley | $44 → $55 | Maintains | Equal-Weight |
| 09/09/2020 | 6977.02% | Morgan Stanley | → $43 | Initiates Coverage On | → Equal-Weight |
| 08/11/2020 | 6483.28% | UBS | $38 → $40 | Maintains | Buy |
| 04/28/2020 | 6154.11% | UBS | $40 → $38 | Maintains | Buy |
| 04/07/2020 | 4672.88% | Baird | $35 → $29 | Maintains | Outperform |
| 04/02/2020 | 5660.37% | Stifel | $38 → $35 | Maintains | Buy |
| 11/15/2019 | 4508.29% | Stifel | → $28 | Initiates Coverage On | → Buy |
What is the target price for NanoString Technologies (NSTG)?
The latest price target for NanoString Technologies (NASDAQ: NSTG) was reported by JP Morgan on November 27, 2023. The analyst firm set a price target for $0.00 expecting NSTG to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NanoString Technologies (NSTG)?
The latest analyst rating for NanoString Technologies (NASDAQ: NSTG) was provided by JP Morgan, and NanoString Technologies downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for NanoString Technologies (NSTG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NanoString Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NanoString Technologies was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating NanoString Technologies (NSTG) correct?
While ratings are subjective and will change, the latest NanoString Technologies (NSTG) rating was a downgraded with a price target of $0.00 to $0.00. The current price NanoString Technologies (NSTG) is trading at is $0.61, which is out of the analyst's predicted range.